FDA Ephedrine Adverse Event Data Questioned By GAO
This article was originally published in The Tan Sheet
Executive Summary
FDA's scientific justification for its proposed rule restricting the use of ephedrine alkaloids in dietary supplements is "open to question," GAO says in a report on the ephedrine proposed rule issued Aug. 4.
You may also be interested in...
Ephedra/AER Causality Link Not Possible - Cantox/CRN
Ephedrine alkaloid adverse event reports recorded in FDA's Special Nutritional Adverse Event Monitoring System do not establish causation between supplements containing the popular weight loss and sports herbal ingredient and reported AEs, according to a report commissioned by the Council for Responsible Nutrition.
Ephedra/AER Causality Link Not Possible - Cantox/CRN
Ephedrine alkaloid adverse event reports recorded in FDA's Special Nutritional Adverse Event Monitoring System do not establish causation between supplements containing the popular weight loss and sports herbal ingredient and reported AEs, according to a report commissioned by the Council for Responsible Nutrition.
Ephedra/AER Causality Link Not Possible - Cantox/CRN
Ephedrine alkaloid adverse event reports recorded in FDA's Special Nutritional Adverse Event Monitoring System do not establish causation between supplements containing the popular weight loss and sports herbal ingredient and reported AEs, according to a report commissioned by the Council for Responsible Nutrition.